You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 204481 - 204490 of 207712 results
  1. Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that respond poorly. Suppressing NF-kB induction as treatment of chronic inflammatory diseases with a primary Th1-type cytokine profile (like e.g. Rheumatoid Arthritis, Multiple sclerosis, Ty ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Nanocarrier formulated enzyme for the treatment of S. aureus infection

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infections including endocarditis, osteomyelitis, catheter related infections, and MRSA-mediated community acquired furunculosis and pneumonia. However, the short half-life of this enzyme in vivo has prec ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Vasoactive intestinal peptide for the treatment of psoriasis

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory skin disease that to this date is only insufficiently controlled by currently available treatments which can also come with severe, and sometimes life threatening side effects. In this application, we propose to create a new class of biologics drug for the treatment of this debilitating disease. We are proposing to formulate ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. EGF/Gastrin for Islet Regeneration

    SBC: PHARMAIN CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet -cells, in combination with immunosuppressant to avoid immune rejection, is restricted to a subgroup of diabetics and is limited b ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder

    SBC: PHARMAIN CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Female sexual arousal disorder (FSAD), one of the conditions commonly described as Female sexual dysfunction (FSD) is common among older women and can be a significant reason for decreased quality of life in the aging population. FSAD is defined as the persistent or recurring inability to attain or maintain sufficient sexual excitement, causing personal distres ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Probabilistic Micromechanical Fatigue Model for Intermetallics

    SBC: VEXTEC Corporation            Topic: N/A

    N/A

    SBIR Phase II 2000 Department of DefenseAir Force
  7. N/A

    SBC: VEXTEC Corporation            Topic: N/A

    N/A

    SBIR Phase I 2000 Department of DefenseAir Force
  8. Reliability Prediction Model for Large, Reusable Propellant Tanks

    SBC: VEXTEC Corporation            Topic: N/A

    NASA has defined goals for development of future reusable launch vehicles (RLV). Systems must be reliable with less than 1 flight failure in 10,000 missions with mission cost of 1000 dollars per pound per payload (or less). X-33 propellant tank incidents indicate need for improving state-of-the-art design and/or manufacture of composite storage tanks. Bond integrity has been an issue during develo ...

    SBIR Phase I 2001 National Aeronautics and Space Administration
  9. Probabilistic Micromechanical High Cycle Fatigue Modeling of Titanium Propulsion Structures

    SBC: VEXTEC Corporation            Topic: N/A

    This effort will develop probabilistic micromechanical fatigue life modeling software . The model will integrate material characterization information with turbine engine structural design methods in order to predict the scatter in the fatigue strength ofa component subjected to high cycle fatigue (HCF). Proven feasible in Phase I, the Phase II will extend our analysis from a simple specimen to in ...

    SBIR Phase I 2001 Department of DefenseAir Force
  10. Probabilistic Micromechanical High Cycle Fatigue Modeling of Titanium Propulsion Structures

    SBC: VEXTEC Corporation            Topic: N/A

    This effort will develop probabilistic micromechanical fatigue life modeling software . The model will integrate material characterization information with turbine engine structural design methods in order to predict the scatter in the fatigue strength ofa component subjected to high cycle fatigue (HCF). Proven feasible in Phase I, the Phase II will extend our analysis from a simple specimen to in ...

    SBIR Phase II 2001 Department of DefenseAir Force
US Flag An Official Website of the United States Government